Analysts split on Amazon RxPass’s impact on GoodRx Holdings By Investing.com

  • Post category:Stock Markets
  • Reading time:2 mins read

Analysts split on Amazon RxPass's impact on GoodRx Holdings © Reuters.   AMZN +0.11% Add to/Remove from a Portfolio Add to Watchlist Add Position

Position added successfully to:

Please name your holdings portfolio Type: BUY SELL Date:   Amount: Price Point Value: Leverage: 1:1 1:10 1:25 1:50 1:100 1:200 1:400 1:500 1:1000 Commission:   Create New Watchlist Create Create a new holdings portfolio Add Create + Add another position Close GDRX -7.77% Add to/Remove from a Portfolio Add to Watchlist Add Position

Position added successfully to:

Please name your holdings portfolio Type: BUY SELL Date:   Amount: Price Point Value: Leverage: 1:1 1:10 1:25 1:50 1:100 1:200 1:400 1:500 1:1000 Commission:   Create New Watchlist Create Create a new holdings portfolio Add Create + Add another position Close

By Sam Boughedda

GoodRx Holdings Inc (NASDAQ:GDRX) shares are down for a second day in a row after Amazon (NASDAQ:AMZN) announced Tuesday that it is rolling out a new product, RxPass, which provides the company’s U.S. Prime members with access to generic medications that treat more than 80 common health conditions for just $5 a month.

GoodRx is currently down more than 9%.

Reacting to the news, Citi analysts, who have a Buy rating and $7 per share price target on GDRX, told investors that while it is still more economical to use GoodRx for consumers taking one drug, for the 30% of Americans using two or more drugs, RxPass will be a “very compelling offering,” particularly for consumers who are already Prime members.

“We also think this will pressure GoodRx Gold membership (which was just raised to $9.99/month), although GoodRx Gold provides additional benefits such as telehealth visits for $19 (vs $35 via Amazon Clinic). We think GoodRx will need to accelerate the pace of product innovation (see for example GDRX’s new commercial offering with ESI to fend off the AMZN threat. We size the max threat at $75-80M of potential lost revenue,” writes the analysts.

Wells Fargo analysts reacted to the news with less worry, stating the RxPass announcement “appears to be more bark than bite.”

“While Amazon’s competitive ambitions shouldn’t be dismissed, the move in GDRX appears overdone, as we estimate RxPass addresses ~0.5% of annual domestic generic Rx volumes,” argued the analysts, who have an Equal Weight rating and $5.50 price target on GoodRx shares.

Analysts split on Amazon RxPass’s impact on GoodRx Holdings  

Leave a Reply